低开低走延续弱势，截止午盘三大指数涨跌互现，其中沪指小跌0.16%，深成指下跌1.85%，创业板指下跌1.81%。两市合计超3600只个股上涨，合计成交 额1.05万亿。 商业航天概念再度爆发，其中盛洋科技2连板，顺灏股份、天银机电、中国卫星等多股涨停。大消费板块走强，零售方向领涨，其中中央商场、上海九百 涨停。IP经济概念表现活跃，其中广博股份、三湘印象涨停。AI医疗概念震荡拉升，其中华人健康20cm涨停。 锂电池板块回落，麒麟电池、电源设备等跌幅居前，其中海科新源、宁德时代下挫。电池、海南板块、多元金融、电子化学品、证券等行业板块紧随其 后。 消息面：中财办扩大内需是明年排在首位的重点任务，明年要把握消费的结构性变化，从供需两侧发力提振消费。蚂蚁集团旗下AI健康应用蚂蚁阿福发 布后下载量猛增，今日冲上苹果应用榜总榜第三位。工信部批准首批L3级自动驾驶车辆量产准入，随后多家车企相继宣布获得L3级路测牌照。 欢迎您在评论中分享自己的看法，大家一起学习和讨论。 ...

| 代码 | 名称 | 现价 | 涨跌幅 | IOPV 溢折率 换手率 成交金额 | | | --- | --- | --- | --- | --- | --- | | 563360 | A500ETF华泰柏瑞 | 1.228 | -0.49% | 1.2280 0.00% 18.54% 69.81亿 | | | 512050 | A500ETF基金 | 1.156 | -0.43% | 1.1556 0.03% 25.26% | 66.22亿 | | 159352 | A500ETF南方 | 1.208 | -0.58% | 1.2087 -0.06% 14.06% | 46.45 Z | | 159361 | A500ETF易方达 | 1.182 | -0.51% | 1.1838 -0.15% 15.31% | 37.36亿 | | 159338 | 中证A500ETF | 1.163 | -0.51% | 1.1638 -0.07% 14.88% | 37.32亿 | | 159351 | A500ETF嘉实 | 1.171 | -0.51% | 1.1731 -0.18% 10.16% | 10.2 ...

12月18日，指数走势分化，逾3600股飘红，半日成交1万亿，较昨日放量212亿。截至午间收盘，上证指 数涨0.16%，深证成指跌0.85%，创业板指跌1.81%。 盘面上，商业航天概念再度爆发，盛洋科技2连板，顺灏股份、天银机电、中国卫星等多股涨停；大消 费板块走强，零售方向领涨，中央商场、上海九百涨停；IP经济概念表现活跃，广博股份、三湘印象涨 停；AI医疗概念震荡拉升，华人健康20cm涨停。下跌方面，电池、证券设备等板块跌幅靠前。 展望后市，中银证券认为，随着地缘政治风险的缓和以及中美政策预期的逐步落地，明年A股的跨年配 置行情有望提前启动，围绕"春躁"布局，可重点关注科技+"反内卷"两条主线。 热门板块 1、商业航天强势 商业航天强势，中国卫星封涨停，此前天银机电、北摩高科、西部材料、天箭科技等多股涨停，航天环 宇、邵阳液压、西测测试跟涨。 点评：消息面上，消息面上，12月17日，据报道，目前正在编制的《上海市加快推进新型工业化 构建 现代化产业体系"十五五"规划》拟聚焦商业航天等。此外，史上最大IPO新动向！SpaceX已通知员工公 司进入"监管静默期"。 2、医药商业反复活跃 医药商业反复活跃，鹭 ...

凤凰网财经讯 12月18日，三大指数涨跌不一，沪指拉升翻红，创业板指跌近2%。黄白线明显分化，微 盘股指数涨超2%。截至午间收盘，沪指涨0.16%，深成指跌0.85%，创业板指跌1.81%。沪深两市半日 成交额1.05万亿，较上个交易日放量212亿。 | | | | | 沪深京重要指数 | | | | --- | --- | --- | --- | --- | --- | --- | | 名称 *● | 咸新 | 涨幅% | | 涨跌 涨跌家数 涨速% | 总手 现手 | 金额 | | 上证指数 | 3876.40 | 0.16 | 6.12 | 1484/763 | -0.02 2.79 7. | 1.76万 4345.11亿 | | 深证成指 | 13111.78 | -0.85 | -112.73 | 2010/815 | -0.08 3.71 亿 | 556 6115.88 Z | | 北证50 | 1448.29 | 0.64 | 9.27 | 136/142 | 0.05 5867 | 1255 134.76 Z | | 创业板指 | 3118.30 | -1.81 | -57.61 | 975/ ...

每经AI快讯，12月18日，三大指数涨跌不一，沪指拉升翻红，创业板指跌近2%。黄白线明显分化，微 盘股指数涨超2%。沪深两市半日成交额1.05万亿元，较上个交易日放量212亿元。盘面上热点快速轮 动，全市场超3600只个股上涨。从板块来看，商业航天概念再度爆发，盛洋科技（603703）2连板，顺 灏股份（002565）、天银机电（300342）、中国卫星（600118）等多股涨停。大消费板块走强，零售方 向领涨，中央商场（600280）、上海九百（600838）涨停。IP经济概念表现活跃，广博股份 （002103）、三湘印象（000863）涨停。AI医疗概念震荡拉升，华人健康（301408）20cm涨停。下跌 方面，锂电池板块回落，海科新源（301292）、宁德时代（300750）下挫。板块方面，医药商业、商业 航天、等板块涨幅居前，电池、证券等板块跌幅居前。截至收盘，沪指涨0.16%，深成指跌0.85%，创 业板指跌1.81%。 ...

早盘，锂矿概念走高，国城矿业（000688）、金圆股份（000546）盘初直线涨停，大中矿业、盛新锂能、盐湖股份等跟涨。港股锂电池股亦走强，截至发 稿，赣锋锂业涨超5%、天齐锂业涨超4%。消息面上，广期所碳酸锂主力合约盘中一度涨超7%，截至发稿仍涨6.78%。 | < V | | | 碳酸锂主连 | | | ra Q | | | --- | --- | --- | --- | --- | --- | --- | --- | | | lcm 广期所 ▼ | | | | | | | | 107780 →チ | 101500 最高 | | | 108300 最低 | | 101500 | | | 6.78% 6840 | 总手 | 51.4万 持仓 | | 70.3万 日增 | | 36540 | | | 结算 | 昨结 | 100940 | | | | 臣令 | | | 分时 五日 | 周长 | 目K | | 目 K | | 更多,◎ | | | 108300 | | | | 7.29% | 卖 1 107780 | | 9 | | | | | | | 买1 107760 | | 28 | | | | | | | ...

Group 1 - The core viewpoint of the news is that Chuangyue Huikang (300451) has been added to the "Alibaba" concept due to its collaborations with Alibaba, Tencent, and related companies in areas such as cloud computing and mobile payments within smart healthcare [1] - The company has other associated concept sectors including AI healthcare, DeepSeek, AI agents, AIGC, data elements, artificial intelligence, Huawei Harmony, Huawei computing power, smart healthcare, Xinchuang, blockchain, family doctors, Internet of Things, DRG-DIP, domestic software, big data, and elderly care [1] - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations, including smart medical health, Internet healthcare, medical IoT, health big data, smart healthcare solutions, system construction and operation, and innovative operational services [1] Group 2 - For the first three quarters of 2025, Chuangyue Huikang reported a main revenue of 862 million yuan, a year-on-year decrease of 26.26% [2] - The company's net profit attributable to shareholders was -122 million yuan, a year-on-year decline of 331.69%, while the non-recurring net profit was -142 million yuan, down 382.12% [2] - In the third quarter of 2025, the company recorded a single-quarter main revenue of 285 million yuan, a year-on-year decrease of 35.5%, with a net profit attributable to shareholders of -41.67 million yuan, down 264.2% [2] - The company's debt ratio stands at 20.27%, with investment income of 4.44 million yuan, financial expenses of -5.32 million yuan, and a gross profit margin of 49.87% [2]

Market Overview - Pharmaceutical and biotechnology stocks showed strong performance, with Shenyuan Biological (688098) hitting a 20% limit up for the third consecutive day [1][6] - The North China 50 Index opened high and rose over 3%, reaching a historical high, while the Shanghai Composite Index and Shenzhen Component Index also saw slight increases [1][2] - The overall market experienced a slight contraction in trading volume [1] Pharmaceutical Sector - Multiple sub-sectors within pharmaceuticals, including innovative drugs, hepatitis concepts, weight-loss drugs, and AI medical concepts, reached historical highs [6] - Significant inflows into the pharmaceutical sector were noted, with over 76 billion yuan in net inflows on the day and a total of over 736 billion yuan in the last 20 trading days [9] - Recent policy support for innovative drugs is expected to drive further growth in the sector, with 534 drugs passing preliminary reviews for inclusion in the national medical insurance directory [8] Robotics Sector - The robotics concept saw a surge, with several stocks hitting their daily limit up, including Southern Precision and Guojiji Precision [3][5] - The Shanghai Municipal Economic and Information Commission announced a plan to accelerate the application of robots in key industries, which is expected to boost the sector [5] Alcohol Sector - The liquor sector experienced a significant rally, with all stocks in the sector rising and the index reaching a new high for the year [10] - Kweichow Moutai and other leading companies showed strong performance, with Moutai launching a series of cultural products aimed at enhancing brand visibility [12] - The sector is attracting attention from stable investors due to its high dividend yields, with the median dividend yield for liquor stocks around 3%, significantly higher than bond yields [12]

Market Performance - The Hong Kong stock market indices experienced a collective decline, with the Hang Seng Index down by 0.63%, the Hang Seng China Enterprises Index down by 0.88%, and the Hang Seng Tech Index down by 0.67% [1] - New consumption concept stocks faced downward pressure, with notable declines in companies such as Nayuki (down 10.12%) and Pop Mart (down 3.33%) [1] - Education stocks also saw significant drops, including a 9.42% decline in Bojun Education [1] Sector Performance - The SaaS and tech-related stocks performed poorly, alongside AI healthcare, internet healthcare, holiday concepts, and automotive sectors [2] - Conversely, the pharmaceutical sector saw gains, with companies like Kangfang Biotech rising by 14.33% and Junshi Biosciences by 11.63% [2] - The recent issuance of measures by the National Healthcare Security Administration and the National Health Commission is expected to support the high-quality development of innovative drugs [2] Apple Supply Chain - Apple-related stocks experienced a rally, with companies like FIH Mobile rising by 4.88% and Sunny Optical Technology by 4.66% [3] - Analysts predict that Apple will launch new MacBook Pro models with OLED screens next year, which could enhance market performance [3] - The global smartphone market is expected to recover, with IDC forecasting a 4% growth in 2024, benefiting Apple and its supply chain [3] Other Notable Movements - Non-ferrous metal stocks and gold stocks saw upward movement, while sectors such as baby products, pork, food, and luxury goods also performed well [4]

Core Viewpoint - The pharmaceutical sector in China is experiencing significant growth, driven by favorable government policies and increasing international market share, with a notable rise in innovative drug development and exports [1][2]. Group 1: Market Performance - On May 23, 2025, pharmaceutical stocks collectively surged, with sectors like Helicobacter pylori, AI healthcare concepts, and weight-loss drugs rising over 2% [1]. - Hai Chen Pharmaceutical's stock hit a 20% limit up within three minutes of opening, reaching a new high in two and a half years [1]. - Heng Rui Pharmaceutical officially listed on the Hong Kong stock market, with its stock price increasing by approximately 30% post-opening, raising about 9.9 billion HKD through an IPO of 224.5 million shares, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [1]. Group 2: Export and Innovation - In Q1 2025, China's pharmaceutical and healthcare product exports reached 26.632 billion USD, a year-on-year increase of 4.39%, while imports decreased by 4.42% to 20.456 billion USD, indicating a domestic industry upgrade and import substitution effect [1][2]. - The United States remains the largest single market for Chinese pharmaceutical exports, with exports amounting to 4.639 billion USD, a 9.6% increase, primarily driven by raw materials and disposable medical supplies [2]. - By the end of 2024, the number of active innovative drugs developed by Chinese companies reached 3,575, ranking first globally, with domestic products accounting for 42% of newly approved innovative drugs, up from less than 10% in 2015 [2]. Group 3: Future Outlook - Analysts predict that 2025 will be a pivotal year for the pharmaceutical industry in China, marking the beginning of significant revenue growth, profitability for many companies, and an extended valuation cycle due to improvements in payment systems [2].